Drug Trial Radar · NCT06736041
Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
Last checked: Nov 19, 2026Latest source record: Apr 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,714
Actual
Start
Dec 18, 2024
Primary completion
May 17, 2027
Study completion May 17, 2027
Sponsor
- Lead sponsor
- Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Dec 16, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 42 days, up to 89 days
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a Phase 3, randomized, modified double-blind study which aims to measure whether PCV21 vaccine (investigational pneumococcal conjugate vaccine) is safe and can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) compared with 20-valent pneumococcal vaccine (Prevnar 20, licensed pneumococcal conjugate vaccine) when they are administered with routine pediatric vaccines in infants aged from approximately 2 months (42 to 89 days). The study duration per participant will be up to approximately 19 months. The study vaccines (either PCV21 or 20-valent pneumococcal vaccines) will be administered at approximately 2, 4, 6 and 12 to 15 months of age. Routine pediatric vaccines will be given at the same timepoints. There will be 6 study visits: -Visit (V)01, V02 separated from V01 by 60 days, V03 separated from V02 by 60 days, V04 separated from V03 by 30 days, V05 at 12 months of age until 15 months of age, V06 separated from V05 by 30 days.
Conditions
- Pneumococcal Immunization
Interventions
PCV21 vaccineBiological
Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
Prevnar 20 vaccineBiological
Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
M-M-R II vaccineBiological
Pharmaceutical form:Powder, lyophilized, for suspension for reconstitution-Route of administration:Subcutaneous or Intramuscular
RotaTeqBiological
Pharmaceutical form:Solution-Route of administration:Oral
Vaxelis vaccineBiological
Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
VarivaxBiological
Pharmaceutical form:Powder, lyophilized, for suspension for reconstitution-Route of administration:Subcutaneous or Intramuscular
Hexaxim VaccineBiological
Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular
Primary outcomes
What the sponsor says the trial is designed to measure.
- Seroresponse rate for PCV21 serotypesTime frame: 30 days post-dose 3
- IgG concentration for PCV21 serotypesTime frame: 30 days post-dose 3
- IgG concentration for PCV21 serotypesTime frame: 30 days post-dose 4
Locations
112 sites in 6 countries. Site status is shown where the registry gives one.
Sun City Clinical Research- Site Number : 8400247
Glendale, Arizona
Eclipse Clinical Research- Site Number : 8400029
Tucson, Arizona
Northwest Arkansas Pediatric Clinic- Site Number : 8400030
Fayetteville, Arkansas
Southland Clinical Research Center- Site Number : 8400243
Fountain Valley, California
Century Research Institute- Site Number : 8400065
Huntington Park, California
Matrix Clinical Research - Huntington Park- Site Number : 8400012
Huntington Park, California
Matrix Clinical Research - Los Angeles- Site Number : 8400013
Los Angeles, California
University of California Los Angeles Medical Center- Site Number : 8400238
Los Angeles, California
Pasadena Clinical Trials - Pasadena - North Madison Avenue- Site Number : 8400259
Pasadena, California
FOMAT Medical Research - Pediatric, Infant & Adolescence Medicine- Site Number : 8400063
Ventura, California
Velocity Clinical Research - Washington DC- Site Number : 8400049
Washington D.C., District of Columbia
PAS Research- Site Number : 8400123
Clearwater, Florida
Prohealth Research Center- Site Number : 8400159
Doral, Florida
NurtureGen Research- Site Number : 8400205
Homestead, Florida
EMDA Clinical Research- Site Number : 8400237
Miami, Florida
Dade Research Center- Site Number : 8400007
Miami, Florida
Acevedo Clinical Research Associates- Site Number : 8400089
Miami, Florida
Miami Clinical Research Tower- Site Number : 8400189
Miami, Florida
Vasconcello-Cohen MD Research, LLC- Site Number : 8400248
Miami, Florida
Bio-Medical Research- Site Number : 8400147
Miami, Florida
High Quality Research- Site Number : 8400245
Miami, Florida
Riveldi Biomedical Research and Associates - Miami Lakes- Site Number : 8400032
Miami Lakes, Florida
BioResearch Partner (BRP) - Premium Healthcare Medical Center - Miami Lakes- Site Number : 8400203
Miami Lakes, Florida
Optimal Research Sites- Site Number : 8400232
Orange City, Florida
SEC Clinical Research - Pensacola- Site Number : 8400003
Pensacola, Florida
National Clinical Trials - Tampa- Site Number : 8400229
Tampa, Florida
PAS Research - Tampa- Site Number : 8400002
Tampa, Florida
Medical Research Partners - Ammon- Site Number : 8400239
Ammon, Idaho
Bingham Memorial Hospital - Blackfoot- Site Number : 8400084
Blackfoot, Idaho
Leavitt Women's Healthcare- Site Number : 8400085
Idaho Falls, Idaho
Snake River Research- Site Number : 8400060
Idaho Falls, Idaho
Clinical Research Prime Rexburg- Site Number : 8400250
Rexburg, Idaho
Alliance for Multispeciality Research - El Dorado- Site Number : 8400010
El Dorado, Kansas
Hutchinson Clinic- Site Number : 8400061
Hutchinson, Kansas
Cotton O'Neil Pediatrics- Site Number : 8400009
Topeka, Kansas
KUR Research at Columbia MD - 6220 Old Dobbin Lane- Site Number : 8400242
Columbia, Maryland
Michigan Institute of Research- Site Number : 8400207
Allen Park, Michigan
University of Missouri Hospital- Site Number : 8400244
Columbia, Missouri
Vector Clinical Trials- Site Number : 8400249
Las Vegas, Nevada
Hawthorne- Bienstar Lindenwold- Site Number : 8400256
Lindenwold, New Jersey
Showing 40 of 112 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.